BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 11106324)

  • 1. Quantification of melanoma cell-specific MART-1 mRNA in peripheral blood by a calibrated competitive reverse transcription-PCR.
    Sørensen BS; Schmidt H; von der Maase H; Straten PT; Nexø E
    Clin Chem; 2000 Dec; 46(12):1923-8. PubMed ID: 11106324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reproducibility of detection of tyrosinase and MART-1 transcripts in the peripheral blood of melanoma patients: a quality control study using real-time quantitative RT-PCR.
    de Vries TJ; Fourkour A; Punt CJ; van de Locht LT; Wobbes T; van den Bosch S; de Rooij MJ; Mensink EJ; Ruiter DJ; van Muijen GN
    Br J Cancer; 1999 May; 80(5-6):883-91. PubMed ID: 10360670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of tumor-associated circulating mRNA in serum, plasma and blood cells from patients with disseminated malignant melanoma.
    Hasselmann DO; Rappl G; Rössler M; Ugurel S; Tilgen W; Reinhold U
    Oncol Rep; 2001; 8(1):115-8. PubMed ID: 11115581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the use of tyrosinase-specific and melanA/MART-1-specific reverse transcriptase-coupled--polymerase chain reaction to detect melanoma cells in peripheral blood samples from 299 patients with malignant melanoma.
    Brownbridge GG; Gold J; Edward M; MacKie RM
    Br J Dermatol; 2001 Feb; 144(2):279-87. PubMed ID: 11251559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of melanoma cells in peripheral blood by reverse transcription-polymerase chain reaction for tyrosinase and MART-1 after mononuclear cell collection with cell preparation tubes: a comparison with the whole blood guanidinium isothiocyanate RNA isolation method.
    de Vries TJ; Fourkour A; Punt CJ; Ruiter DJ; van Muijen GN
    Melanoma Res; 2000 Apr; 10(2):119-26. PubMed ID: 10803712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative RT-PCR assessment of melanoma cells in peripheral blood during immunotherapy for metastatic melanoma.
    Schmidt H; Sørensen BS; von der Maase H; Bang C; Agger R; Hokland M; Nexo E
    Melanoma Res; 2002 Dec; 12(6):585-92. PubMed ID: 12459648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular detection of MART-1, tyrosinase and MIA in peripheral blood, lymph nodes and metastatic sites of stage III/IV melanoma patients.
    Enk CD; Lotem M; Gimon Z; Hochberg M
    Melanoma Res; 2004 Oct; 14(5):361-5. PubMed ID: 15457091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multimarker quantitative real-time PCR detection of circulating melanoma cells in peripheral blood: relation to disease stage in melanoma patients.
    Koyanagi K; Kuo C; Nakagawa T; Mori T; Ueno H; Lorico AR; Wang HJ; Hseuh E; O'Day SJ; Hoon DS
    Clin Chem; 2005 Jun; 51(6):981-8. PubMed ID: 15817820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multimarker real-time reverse transcription-PCR for quantitative detection of melanoma-associated antigens: a novel possible staging method.
    Arenberger P; Arenbergerova M; Gkalpakiotis S; Lippert J; Stribrna J; Kremen J
    J Eur Acad Dermatol Venereol; 2008 Jan; 22(1):56-64. PubMed ID: 18181974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of melanoma cells in the blood of melanoma patients by melanoma-inhibitory activity (MIA) reverse transcription-PCR.
    Mühlbauer M; Langenbach N; Stolz W; Hein R; Landthaler M; Buettner R; Bosserhoff AK
    Clin Cancer Res; 1999 May; 5(5):1099-105. PubMed ID: 10353744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymerase chain reaction-based detection of circulating melanoma cells as an effective marker of tumor progression. Melanoma Cooperative Group.
    Palmieri G; Strazzullo M; Ascierto PA; Satriano SM; Daponte A; Castello G
    J Clin Oncol; 1999 Jan; 17(1):304-11. PubMed ID: 10458247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantification of melanoma mRNA markers in sentinel nodes: pre-clinical evaluation of a single-step real-time reverse transcriptase-polymerase chain reaction assay.
    Abrahamsen HN; Nexo E; Steiniche T; Hamilton-Dutoit SJ; Sorensen BS
    J Mol Diagn; 2004 Aug; 6(3):253-9. PubMed ID: 15269303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative assessment of the expression of melanoma-associated antigens by non-competitive reverse transcription polymerase chain reaction.
    Ringhoffer M; Schmitt M; Karbach J; Jäger E; Oesch F; Arand M
    Int J Oncol; 2001 Nov; 19(5):983-9. PubMed ID: 11604998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Magnetic bead RT-PCR: establishment of a new method for detecting circulating melanoma cells.
    Georgieva J; Milling A; Orfanos CE; Geilen CC
    Melanoma Res; 2002 Aug; 12(4):309-17. PubMed ID: 12170179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased sensitivity for the detection of malignant melanoma cells in peripheral blood using an improved protocol for reverse transcription-polymerase chain reaction.
    Schittek B; Blaheta HJ; Flörchinger G; Sauer B; Garbe C
    Br J Dermatol; 1999 Jul; 141(1):37-43. PubMed ID: 10417513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peripheral blood tyrosinase messenger RNA detection and survival in malignant melanoma.
    Kunter U; Buer J; Probst M; Duensing S; Dallmann I; Grosse J; Kirchner H; Schluepen EM; Volkenandt M; Ganser A; Atzpodien J
    J Natl Cancer Inst; 1996 May; 88(9):590-4. PubMed ID: 8609659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial.
    Koyanagi K; O'Day SJ; Gonzalez R; Lewis K; Robinson WA; Amatruda TT; Wang HJ; Elashoff RM; Takeuchi H; Umetani N; Hoon DS
    J Clin Oncol; 2005 Nov; 23(31):8057-64. PubMed ID: 16258104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of a HLA-A2 tetramer flow cytometric method, IFNgamma real time RT-PCR, and IFNgamma ELISPOT for detection of immunologic response to gp100 and MelanA/MART-1 in melanoma patients.
    Xu Y; Theobald V; Sung C; DePalma K; Atwater L; Seiger K; Perricone MA; Richards SM
    J Transl Med; 2008 Oct; 6():61. PubMed ID: 18945350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating tyrosinase and MART-1 mRNA does not independently predict relapse or survival in patients with AJCC stage I-II melanoma.
    Schmidt H; Sorensen BS; Sjoegren P; Christensen IJ; Fode K; Larsen J; Nexo E; von der Maase H
    J Invest Dermatol; 2006 Apr; 126(4):849-54. PubMed ID: 16410782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular strategy for detecting metastatic cancers with use of multiple tumor-specific MAGE-A genes.
    Miyashiro I; Kuo C; Huynh K; Iida A; Morton D; Bilchik A; Giuliano A; Hoon DS
    Clin Chem; 2001 Mar; 47(3):505-12. PubMed ID: 11238304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.